Roots Analysis

JANUARY 28, 2024

Big Data in healthcare refers to the vast amount of data that is continuously expanding and cannot be efficiently stored or processed using traditional tools. It accounts for the majority of big data in healthcare and comprises information, such as medical images, surveys, chats, and written narratives.

Big Data 40

Big Data Medicine Marketing Clinical Trials 40

Drug Discovery World

JULY 11, 2023

Drug discovery and development timelines can span 10-15 years or more from initial discovery to market approval and typically require the analysis of massive amounts of data. How AI and ML are influencing drug development Biopharma has experienced significant growth in using these technologies for the past 10 years.

Big Data 40

Big Data Development Life Science Drugs 40

Drug Discovery World

MAY 4, 2023

Professor Sonika Bhatnagar explores how artificial intelligence is enabling drug discovery at rates never seen before. Here started the story of drug discovery. The magic bullet was the drug, while the specific mark it would reach in the syphilis causing bacteria to eliminate the disease was the drug target.

Medicine 52

Medicine Protein Drugs Bioassay 52

Drug Discovery World

FEBRUARY 6, 2024

As AI-designed drugs start to enter large-scale clinical trials, DDW’s Diana Spencer investigates how new digital tools are reinventing and reshaping drug discovery for the future. Auransa, which harnesses available data to discover highly intractable diseases with poorly understood biology.

Marketing 69

Marketing Medicine Genome Genomics 69

XTalks

AUGUST 2, 2023

Pfizer’s Top 5 Best-Selling Drugs of 2022: 1) Comirnaty Comirnaty is an mRNA-based vaccine indicated for the prevention of COVID-19. Comirnaty was first approved by the US Food and Drug Administration (FDA) in August 2021 for individuals over the age of 16. billion the drug generated in 2021. billion in 2022. billion, a 26.55

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Drug Discovery World

SEPTEMBER 6, 2022

There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. Among these include Zolgensma, Novartis’ gene therapy drug for spinal muscular atrophy (SMA), which made headlines in the UK for its £1.79 million price point per dose. Chris Nowers, CEO, ONK Therapeutics. . “

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52